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ABSTRACT 
Objective: To develop and validate simple, sensitive stability indicating HPTLC (High performance thin layer chromatography) method for 
apixaban. 
Methods: The chromatographic separation was performed on aluminium plates precoated with silica gel 60 F254
Results: The chromatographic condition shows sharp peak of apixaban at Rf value of 0.38±0.03. Stress testing was carried out according to 
international conference on harmonization (ICH)Q1A (R2) guidelines and the method was validated as per ICH Q2(R1) guidelines. The calibration 
curve was found to be linear in the concentration range of 100-500 ng/band for apixaban. The limit of detection and quantification was found to be 
11.66ng/bandand35.33ng/band, respectively. 
 using toluene: ethyl acetate: 
methanol (3:6:1 v/v/v) as mobile phase followed by densitometric scanning at 279 nm. 
Conclusion: A new simple, sensitive, stability indicating high performance thin layer chromatographic (HPTLC) method has been developed and 
validated for the determination of apixaban. 
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Apixaban is an oral anticoagulant and direct inhibitor of factor Xa, 
which is used to decrease the risk of venous thrombosis, systemic 
embolization and stroke in patients with atrial fibrillation. 
Apixaban has been linked to a low rate of serum aminotransferase 
elevations during therapy and to rare instances of clinically apparent 
liver injury [1]. Apixaban is chemically described as 1-(4-
methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-
tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide. Its molecular 
formula is C25H25N5O4
Apixaban was approved for the prevention of stroke, blood clots in 
patients with non-valvular atrial fibrillation on December 28, 2012 
[3]. On March 14 2014 it was approved for the use of 
preventing deep vein thrombosis in adult patients who have 
undergone total knee or hip replacement surgery [4].  
 and molecular weight is 459.5 (fig. 1) [2]. 
On August 21, 2014, the food and drug administration (FDA) 
approved apixaban for the treatment of recurring deep vein 
thrombosis and pulmonary embolism [5]. Apixaban is not official in 
any of the Pharmacopoeia (USP, BP, EP–checked by online, IP-2014). 
According to literature survey,there are some HPLC, 
spectrofluorimetric and HPTLC methods reported for determination 
of apixaban [6-9] and hyphenated techniques such as LC-MS [10], 
UHPLC–MS/MS [11], either alone or ina combination tirofiban 
hydrochloride or with rivaroxaban. 
To the best of our knowledge, no stability indicating HPTLC method 
has been reported for the determination of apixabanas bulk drug. 
The core-objective of this research work was to develop a simple, 
accurate, precise, and stability-indicating HPTLC method for the 
determination of apixaban as bulk drug. 
MATERIALS AND METHODS 
Apixaban was provided as a gift sample by wockhardt research and 
development centre, Aurangabad. Ethyl acetate AR grade purchased 
from FINAR chemicals ltd. methanol, toluene, and all other chemicals 
used in this study were of AR grade purchased from LOBA 
chemiepvt. ltd. Mumbai, India. 
Chemicals and reagents 
Linomat-5 sample applicator (Camag, Switzerland), twin trough 
chamber (10 x 10 cm; Camag, Switzerland), TLC scanner 3 (Camag, 
Switzerland), WinCATS version 1.4.3 software (Camag, Switzerland), 
Photostability chamber (Newtronics NEC103RSPI), Shimadzu 
balance (Model AY-120), Camag100 µl sample syringe (Hamilton, 
Switzerland) were used in the study. 
Instruments 
Standard stock solution of apixaban was prepared by dissolving 10 
mg of the drug in 10 ml of methanol to get concentration of 
1000µg/ml. From the standard stock solution, working standard 
solution was prepared containing 20µg/ml of apixaban. 
Preparation of standard solutions 
The standard solution of apixaban of concentration 10µg/ml was 
prepared using methanol and scanned over the wavelength range 
200 nm to 400 nm by using UV-Visible spectrophotometer. λ
Selection of analytical wavelength 
max was 
found to be 279 nm (fig. 2). 
Initially, mobile phase optimization trials were conducted using 
(Chloroform: methanol in the ratios as 5:5, 7:3, 3:7), (Toluene: ethyl 
acetate-5:5, 7:3, 3:7). Optimized mobile phase was toluene: ethyl 
acetate: methanol (3:6:1 v/v/v). TLC plates precoated with silica gel 
60 F
Chromatographic conditions 
254, of dimension 10 cm × 10 cm with 250 µm layer thickness 
were used as stationary phase. TLC plates were pre-washed with 
methanol and dried. The standard solution of apixaban was spotted 
on the dried, pre-coated TLC plate as a band with 4 mm width. The 
chromatographic development was carried out by using toluene: 
ethyl acetate: methanol (3:6:1 v/v/v) as mobile phase with 15 min 
chamber saturation time and run up to distance 90 mm. 
Densitometric scanning was performed at 279 nm.  
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Optimization of mobile phase 
Method development for apixaban was started with the 
development of densitogram using neat solvents and combinations 
of toluene, ethyl acetate and methanol in different ratios. Toluene: 
ethyl acetate: methanol in the ratio of (3:6:1 v/v/v) was selected as 
mobile phase for apixaban which gives accepted peak parameters. 
The Rf was found to be 0.38±0.03 for apixaban. The standard 
densitogram of apixaban (200ng/band) is shown in (fig. 3). 
Stress degradation studies of bulk drug 
Stress testing studies were carried out to provide evidence on how 
the quality of drug varies under various stress conditions like 
oxidation, hydrolysis, photolysis and thermal, etc. Stress degradation 
studies were designed by referring some papers [12-15]. 
Optimization of stress conditions was done by changing the strength 
of reagent and duration of exposure to get 10-30 % degradation. The 
stress degradation study was carried out as per ICH Q1A (R2) and 
Q1 B [16, 17]. 
Optimization trials 
Initially trials were conducted using various normalities of HCl and 
NaOH by keeping the sample solution overnight. For the thermal 
study sample was heated at 80 °C for 4 h to 8 h and for oxidation, 
trials were conducted using 30 % H2O2by keeping the sample 
solution overnight. It was observed that the drug gets degraded 
partially. 
Optimized stress conditions 
Alkaline hydrolysis 
1 ml working standard solution of apixaban (200 µg/ml) was mixed 
with 1 ml of 1 N NaOH and volume was made up to 10 ml with 
methanol. The solution was kept overnight. Average 69.41 % of 
apixaban was recovered with no peak of degradation. 
Acid hydrolysis 
5 ml standard solution of Apixaban (200 μg/ml) was mixed with 5 
ml of 0.5 N HCl and volume was made up to 50 ml using methanol. 
The solution was refluxed for 30 min and cooled to room 
temperature. Average 76.48 % of apixaban was recovered with no 
peak of degradation. 
Oxidative degradation 
1 ml standard solution of apixaban (200 μg/ml) was mixed with 4 ml 
30% v/v H2O2
Validation parameter 
, volume was made up to 10 ml using methanol. 
Average 95% of apixaban was recovered with no peak of 
degradation after 30 min. 
Degradation under dry heat 
Dry heat study was performed by keeping the drug in hot air oven at 
80 °C for 8 h. Average 77.20 % of apixaban was recovered with no 
peak of degradation. 
Degradation under neutral condition  
To 5 ml of 200µg/ml solution of apixaban, 5 ml of distilled water was 
added. The volume was made upto 50 ml with methanol. The above 
solution was refluxed for 2 h and then cooled. Average 91.48% of 
apixaban was recovered with no peak of degradation. 
Photo-degradation studies  
Photolytic degradation studies were carried out by exposure of drug 
to UV light up to 200 watt h/m2 and subsequently to cool white 
fluorescent light to achieve an illumination of 1.2 million Lux h. The 
sample was weighed, dissolved and diluted get 20μg/ml as final 
concentration and was applied to TLC plate. After the photo 
degradation study under UV light 100% and Fluorescence light 
98.78% apixaban was recovered with no peak of degradation. 
Spotting of 2000ng/band was done for samples at each stress 
condition to locate peak for a degradation product if any. 
The developed method was successfully validated according to the 
ICH Q2 (R1) guidelines [18]. 
Specificity 
The specificity of the method was ascertained by analyzing standard 
drug and sample. The spot for the drug in a sample was confirmed 
by comparing the Rf and the spectra of the spot with that of the 
standard drug spot. The specificity of the method was also 
ascertained by peak purity profiling studies by analyzing the 
spectrum at peak start, middle and at the peak end. 
Linearity and range 
The calibration curve was obtained in the range of 100-500ng/band 
by applying different volumes (5-25 µl) of stock solution of (20 
μg/ml) ona TLC plate. Each standard in five replicates was analyzed 
and peak areas were recorded. The relationship between peak area 
and concentration was established bythe simple regression equation 
method (fig. 4). 
Assay  
5 tablets were accurately weighed and powdered. From the powder, 
an amount equivalent to 5 mg of apixaban was accurately weighed 
and transferred to 10 ml volumetric flask. Methanol was added, 
sonicated for 15 min, a solution was filtered. Dilutions were made to 
get the final concentration20µg/ml. The assay was calculated by 
extrapolation from standard curve which was found to be 101.02 % 
Accuracy 
To check accuracy of the method, recovery studies were carried out 
by adding a standard drug to sample at three different levels 80, 100 
and 120 %. Basic concentration of the sample chosen was 
200ng/band. The drug concentrations were calculated by using the 
regression equation of apixaban.  
Precision 
The precision of the method was demonstrated by intra-day and 
inter-day studies. In the intra-day studies, 3 replicates of 3 standard 
solutions were analyzed in a same day and percentage RSD was 
calculated. For the inter-day, 3 standard solutions were analyzed on 
three consecutive days and percentage RSD was calculated. 
Method sensitivity ‘Limit of detection’ (LOD) and ‘limit of 
quantification’ (LOQ) 
LOD and LOQ were calculated as 3.3 σ/S and 10 σ/S respectively. 
Where σ is the standard deviation of the lowest concentration 
response and S is the slope of the calibration plot. The LOD and LOQ 
were found to be11.66ng/band and 35.33ng/band respectively. 
Robustness 
The robustness of the method were studied during method 
development, by small but deliberate variations in chamber 
saturation time (13, 17 min), change in mobile phase composition, 
Time was changed from spotting to development and development 












Fig. 1: Chemical structure of apixaban
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2: UV spectrum of apixaban between 200-400 nm 
 
Fig. 3: Densitogram of standard solution of apixaban 200 ng/band Rf(0.38±0.03) 
 
 
Fig. 4: Densitogram of standard solution of apixaban (100-500ng/band) 
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Fig. 5: Calibration curve of apixaban 
 
Stress degradation 
Initially the drug was subjected to various forced degradation 
conditions. The conditions of stress were optimized with respect to 
the strength of the reagent and exposure period so as to achieve 10 
to 30 % degradation. During optimization, degradation condition 
was adjusted by the increase and decrease in concentration and 
strength of reagent and its time of exposure.  
Summary of stress degradation results is given in (table 1). 
 
Table 1: Summary of stress degradation study of apixaban (n=2) 
Stress degradation condition % Recovery % Degradation Peak purity 
r(s, m) r(m, e) 
Acid (0.5 N HCl) reflux for 30 min 76.48 23.52 0.999 0.993 
Base (1 N NaOH, overnight) 69.41 30.59 0.999 0.995 
Oxidation (30% v/v H2O2) 95 30 min 5.0 0.999 0.997 
Neutral reflux 2 h 91.48 8.52 0.999 0.995 
Dry heat (80 °C 8 h) 77.20 22.8 0.999 0.998 
Photo stability UV 200 watt h/m2 100 - 0.999 0.992 
Flourescence 1.2 million lux. h 98.78 1.22 0.999 0.994 
n = number of determinations for each conditions 
 
Method validation 
Table 2: Result of accuracy (recovery) study of apixaban (n=3) 





Sample conc Amount added 
200 160 361.22 100.42±1.32 1.31 
200 200 402.95 100.73±1.06 1.05 
200 240 437.85 99.51±0.85 0.86 
n = number of determinations, SD = Standard Deviation, %RSD = %Relative Standard Deviation 
 
Table 3: Intra-day precision (n=3) 
Concentration (ng/band) Area (mean±SD) %RSD 
100 3120.07±39.82 1.27 
200 5409.03±56.67 1.04 
300 6629.97±64.78 0.97 
n = number of determinations 
 
Table 4: Inter-day precision (n=3) 
Concentration (ng/band) Area(mean±SD) %RSD 
100 3128.73±40.76 1.30 
200 5443.3±49.74 0.91 
300 6534.03±56.37 0.86 
n = number of determinations 
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Table 5: Robustness study of apixaban (n=3) 




Chamber saturation time (15 min)±2 min 13 min 4568.67±75.51 1.65 
17 min 4363.8±29.84 0.68 
Mobile phase composition toluene: ethyl acetate: methanol (3:6:1 
v/v)±0.2 methanol 
Toluene: ethyl acetate: methanol (3:6:0.8) 4449.4±49.34 1.10 
Toluene: ethyl acetate: methanol (3:6:1.2) 4694.67±54.40 1.16 
Time from application to development (immediate) After 30 min 2872.67±34.29 1.19 
After 1 h 3081.43±54.52 1.76 
Time from development to scanning(immediate) After 30 min 3068.17±53.61 1.74 
After 1 h 3062.93±57.66 1.88 
n = number of determinations, SD = Standard Deviation, %RSD = %Relative Standard Deviation 
 
The method validation results were satisfactory as per ICH Q2R1 
guidelines. The peak area was found to be linear over the concentration 
range of 100-500 ng/band with a correlation coefficient of 0.984. Method 
specificity can be proved using peak purity parameter in WinCATS 
software of HPTLC. There is a provision to compare the UV spectrum at the 
start, middle and end of any peak. Inter and Intra-day precision was less 
than 2%. Percent recovery in an accuracy study was within the limit of 98 
to 102 %. The results of validation are summarized in table 6. 
 
Table 6: Summary of validation parameter 
Validation parameter Results 
Linearity Y = 15.05x+1975 R2 = 0.984 















LOD 11.66 ng/band 





While developing stability indicating method, in the current work, 
the stress conditions were optimized to achieve 10-30% 
degradation. In the literature survey, it observed that the 
degradation pattern under alkaline hydrolytic conditions reported 
in work by landge et al. [7] and prabhune et al. [6], do not match at 
all. Our results fairly match the ones reported by landge et al. except 
for the degradation product. Apixaban was found to be fairly stable 
to photo-degradation. Both the reported papers do not have mention 
of neutral hydrolysis. These papers report Apixaban to be thermally 
stable but we have observed degradation to an extent of 22.8% 
CONCLUSION 
The developed method is simple, sensitive, and precise. No 
degradation product was observed with the optimized stress 
conditions. Non-interference has been proved by peak purity 
studies. Since there is no interference, this method can be used 
routinely for estimation of apixaban.  
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